SandboxAQ has expanded its strategic alliance with Deloitte to offer AI-powered Large Quantitative Model (LQM) simulations alongside Deloitte’s life sciences and technology expertise. This collaboration aims to accelerate drug discovery, materials science, and biopharma innovations through advanced AI simulations.
AI-Driven Innovation with Large Quantitative Models (LQMs)
Traditional drug discovery methods are time-consuming and resource-intensive. LQMs represent the next frontier of AI, leveraging physics-based simulations to optimize research and development in biopharma and materials science.
Solutions in the Collaboration:
AQBioSim & AQChemSim – AI-driven simulation tools that enhance drug discovery and molecular research.
Deloitte’s Atlas AI™ – A knowledge graph-based AI engine that extracts highly accurate clinical hypotheses from scientific literature.
Automated Data Evaluation – AI models that improve target identification, treatment response analysis, and exploratory data analysis.
“AI simulation with Large Quantitative Models represents the next evolution of AI and will have a transformative impact on how organizations create value for their customers,” said Andrew McLaughlin, COO of SandboxAQ.
The Impact on Drug Discovery and Life Sciences
By combining SandboxAQ’s AI molecular simulations with Deloitte’s deep industry expertise, organizations can:
Accelerate Drug Development – Faster identification of promising compounds and treatment pathways.
Enhance Precision & Accuracy – AI-powered simulations improve data validation and predictive modeling.
Optimize Research Efficiency – Reduce trial-and-error experimentation through data-driven insights.
“Together, we aim to advance drug discovery and materials science for leading academic, commercial, and public sector entities,” said Aditya Kudumala, Principal, Deloitte Consulting LLP.
The SandboxAQ-Deloitte collaboration marks a significant step forward in AI-driven scientific research, offering pharmaceutical and life sciences organizations unparalleled tools for accelerating innovation. This partnership will reshape the future of drug discovery and molecular science, providing organizations with cutting-edge AI-powered solutions.
